Lakewood-Amedex Biotherapeutics Inc. (LABT) stock
LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.21−0.00 (-2.23%)
Close on Nov 17, 2026Market cap $508.30KP/E –Yield –
Lakewood-Amedex Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Lakewood-Amedex Biotherapeutics's cash was $3.32M at Sep 30, 2026. For fiscal 2025 it was $236.40K, down 65.3% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $236.40K | -65.3% |
| FY2024 | Dec 31, 2024 | $681.10K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.32M | +404.8% |
| Q2 FY2026 | Jun 30, 2026 | $4.58M | +261.4% |
| Q1 FY2026 | Mar 31, 2026 | $11.71K | -97.5% |
| Q4 FY2025 | Dec 31, 2025 | $236.40K | -65.3% |
| Q3 FY2025 | Sep 30, 2025 | $658.41K | – |
| Q2 FY2025 | Jun 30, 2025 | $1.27M | – |
| Q1 FY2025 | Mar 31, 2025 | $477.01K | – |
| Q4 FY2024 | Dec 31, 2024 | $681.10K | – |
See a number that looks wrong?